ARIAD Pharmaceuticals Inc. (ARIA)
Symbol Info
Listed Symbol ARIA
Name ARIAD Pharmaceuticals Inc.
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2015-12-31
Latest Fiscal Revenue $118,804,000
Latest Fiscal EPS $-1.22
Price Info
21 Day Moving Average $23.8041
21 Day EMA $23.072350
50 Day Moving Average $18.8621
50 Day EMA $20.063970
200 Day EMA $13.610200
200 Day Moving Average 12.167250
52 Week High $23.99
52 Week Low $4.67
52 Week Change $393.621400
Alpha 0.032150
Beta 2.1779
Standard Deviation 0.273819
R2 0.054699
Periods 60
Share Information
10 Day Average Volume 4,867,204
20 Day Average Volume 8,015,426
30 Day Average Volume 15,897,303
50 Day Average Volume 11,008,718
Outstanding Shares 194,200,862
Float Shares 189,097,694
Percent Float 97.37%
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 270
Institute Holdings Date 2016-12-31
Institute Bought Previous 3 Months 28,456,134
Institute Holdings Percent 88.200000
Institute Sold Previous 3 Months 19,584,565
Insider Holdings Date
Insider Bought Previous 3 Months -
Insider Holdings Percent -
Insider Sold Previous 3 Months -
Insiders Shares Owned 5,103,168
Price Change
7 Day Price Change $0.1000004
7 Day Percent Change 0.42%
21 Day Price Change $0.3500004
21 Day Percent Change 1.48%
30 Day Price Change $0.2999992
30 Day Percent Change 1.27%
Month To Date Price Change $0.1700
Month To Date Percent 0.71%
90 Day Price Change $11.120000
90 Day Percent Change 86.40%
Quarter To Date $11.550000
Quarter To Date Percent 92.85%
180 Day Price Change $13.440000
180 Day Percent Change 127.39%
200 Day Price Change $14.480000
200 Day Percent Change 152.26%
Year To Date $11.550000
Year To Date Percent 92.85%
Profile
Description Ariad Pharmaceuticals is a biotechnology company with a focus on cancer drugs. The global oncology company aims to discover, develop, and commercialize small-molecule medicines to treat aggressive cancers where current therapies are inadequate, including leukemia. The vast majority of Ariad's revenue is derived from its product revenue segment, followed by its license collaboration and other revenue segments. The United States represents a majority of the company? oncology profits based on roughly half of its global sales. Ariad seeks market share outside the U.S. through industry partnerships.
Details
Issue Type CS
Market Cap $4,658,878,679
Sec Type EQS
Auditor Deloitte & Touche LLP
Total Shares Outstanding -
CEO Paris Panayiotopoulos
Employees 459
Last Audit UQ
Classification
CIK 0000884731
Industry Biotechnology
Sector Healthcare
NAICS Biological Product (except Diagnostic) Manufacturing(325414)
Info
Address 26 Landsdowne Street
Cambridge, MA 02139-4234
Website http://www.ariad.com
Facisimile +1 617 494-8144
Telephone +1 617 494-0400
Email manmeet.soni@ariad.com
Key Ratios
Profitability
EBIT Margin -3.2
EBITDA Margin 5.0
Pre-Tax Profit Margin -8,146.4
Profit Margin Cont 18.86
Gross Margin 98.30
Profit Margin TOT 18.86
Income Statements
Revenue $149,739,000
Revenue Per Share $0.7711
Revenue 3 Years $43.35
Revenue 5 Years $91.13
Valuation Measures
PE Ratio -
Enterprise Value $4,897,132,679
Price To Sales 31.113325
Price To Free Cash -28.9
PE High Last 5 Years -
Price To Book 40.5
Price To Cash Flow 299.0
PE Low Last 5 Years -
Price To Tangible Book -98.7
Financial Strength
Total Debt To Equity -
Int Coverage -0.3
Current Ratio 3.2
Leverage Ratio -7.6
Quick Ratio 3.1
Long Term Debt To Capital -
Assets
Receivables Turnover 7.5
Invoice Turnover 2.00
Assets Turnover 0.20
Management Effectiveness
Return Assets -5.04
Return On Equity 65.81
Return On Capital -
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type


Your Recent History
NASDAQ
ARIA
Ariad
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.